{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:18:45Z","timestamp":1775096325580,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Pim1 (proviral integration site for Moloney leukemia virus 1) protein is a serine\/threonine kinase that is essential for cell proliferation, apoptosis and innate immune responses. Here we show that Pim1 promotes osteoclast resorptive function without affecting osteoclast numbers. Specifically, we found that mice lacking Pim1 (<jats:italic>Pim1<\/jats:italic>\n            <jats:sup>\u2212\/\u2212<\/jats:sup>) developed increased trabecular bone mass and indices such as trabecular bone-mass density. This was due to the direct phosphorylation of TRAF6 by Pim1 in mature osteoclasts, which activated the Akt\u2013GSK3\u03b2 signaling pathway. This, in turn, promoted the acetylation and consequent stabilization of microtubules, which permitted the formation of the osteoclast sealing zone. In vivo experiments then showed that, when mice with lipopolysaccharide-induced bone loss or tumor-induced osteolysis were treated with SGI-1776, a Pim1 inhibitor that is more selective for Pim1, the bone loss was significantly ameliorated. Thus, Pim1 plays an important role in osteoclast function and may be a therapeutic target for bone-related diseases.<\/jats:p>","DOI":"10.1038\/s12276-025-01421-4","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:10:00Z","timestamp":1743466200000},"page":"733-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pim1 promotes the maintenance of bone homeostasis by regulating osteoclast function"],"prefix":"10.1038","volume":"57","author":[{"given":"Jeongin","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryeojin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-0067","authenticated-orcid":false,"given":"Woojin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2590-3084","authenticated-orcid":false,"given":"Soo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115628","volume":"141","author":"JM Delaisse","year":"2020","unstructured":"Delaisse, J. M. et al. Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 141, 115628 (2020).","journal-title":"Bone"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","volume":"6","author":"X Feng","year":"2011","unstructured":"Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu. Rev. Pathol. 6, 121\u2013145 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508\u20131514 (2000).","journal-title":"Science"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","volume":"20","author":"DL Waning","year":"2014","unstructured":"Waning, D. L. & Guise, T. A. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin. Cancer Res. 20, 3071\u20133077 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41413-020-00105-1","volume":"8","author":"M Wang","year":"2020","unstructured":"Wang, M., Xia, F., Wei, Y. & Wei, X. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res. 8, 30 (2020).","journal-title":"Bone Res."},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2017.11.016","volume":"414","author":"C Lee","year":"2018","unstructured":"Lee, C. et al. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett. 414, 205\u2013213 (2018).","journal-title":"Cancer Lett."},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/cco.2020.01.07","volume":"9","author":"L Rossi","year":"2020","unstructured":"Rossi, L., Longhitano, C., Kola, F. & Del Grande, M. State of art and advances on the treatment of bone metastases from breast cancer: a concise review. Chin. Clin. Oncol. 9, 18 (2020).","journal-title":"Chin. Clin. Oncol."},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032\u20131045 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","volume":"44","author":"IR Reid","year":"2009","unstructured":"Reid, I. R. Osteonecrosis of the jaw: who gets it, and why? Bone 44, 4\u201310 (2009).","journal-title":"Bone"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.1080\/21655979.2022.2060584","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X., Xu, R., Ye, J. X. & Yuan, F. L. Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p. Bioengineered 13, 9741\u20139753 (2022).","journal-title":"Bioengineered"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.14348\/molcells.2017.0225","volume":"40","author":"JH Park","year":"2017","unstructured":"Park, J. H., Lee, N. K. & Lee, S. Y. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells 40, 706\u2013713 (2017).","journal-title":"Mol Cells"},{"key":"1421_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337\u2013342 (2003).","journal-title":"Nature"},{"key":"1421_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4161\/cam.27840","volume":"8","author":"D Georgess","year":"2014","unstructured":"Georgess, D., Machuca-Gayet, I., Blangy, A. & Jurdic, P. Podosome organization drives osteoclast-mediated bone resorption. Cell Adh. Migr. 8, 191\u2013204 (2014).","journal-title":"Cell Adh. Migr."},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bone.2006.04.010","volume":"39","author":"S Okumura","year":"2006","unstructured":"Okumura, S. et al. Coordination of microtubules and the actin cytoskeleton is important in osteoclast function, but calcitonin disrupts sealing zones without affecting microtubule networks. Bone 39, 684\u2013693 (2006).","journal-title":"Bone"},{"key":"1421_CR15","doi-asserted-by":"crossref","unstructured":"Blangy, A. et al. The osteoclast cytoskeleton\u2014current understanding and therapeutic perspectives for osteoporosis. J. Cell Sci. 133, jcs244798 (2020).","DOI":"10.1242\/jcs.244798"},{"key":"1421_CR16","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1242\/jcs.02425","volume":"118","author":"O Destaing","year":"2005","unstructured":"Destaing, O. et al. A novel Rho\u2013mDia2\u2013HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. J. Cell Sci. 118, 2901\u20132911 (2005).","journal-title":"J. Cell Sci."},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1083\/jcb.200701148","volume":"178","author":"H Gil-Henn","year":"2007","unstructured":"Gil-Henn, H. et al. Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2\u2212\/\u2212 mice. J. Cell Biol. 178, 1053\u20131064 (2007).","journal-title":"J. Cell Biol."},{"key":"1421_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/jbmr.241","volume":"26","author":"JM Hong","year":"2011","unstructured":"Hong, J. M. et al. Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J. Bone Miner. Res. 26, 657\u2013665 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"1421_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s12276-022-00820-1","volume":"54","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J. et al. Phospholipase D2 controls bone homeostasis by modulating M-CSF-dependent osteoclastic cell migration and microtubule stability. Exp. Mol. Med. 54, 1146\u20131155 (2022).","journal-title":"Exp. Mol. Med."},{"key":"1421_CR20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/jbmr.1844","volume":"28","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto, T. et al. Regulation of bone resorption and sealing zone formation in osteoclasts occurs through protein kinase B-mediated microtubule stabilization. J. Bone Miner. Res. 28, 1191\u20131202 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"1421_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","volume":"37","author":"M Bachmann","year":"2005","unstructured":"Bachmann, M. & Moroy, T. The serine\/threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 37, 726\u2013730 (2005).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s10495-016-1289-3","volume":"21","author":"GG Jinesh","year":"2016","unstructured":"Jinesh, G. G., Mokkapati, S., Zhu, K. & Morales, E. E. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. Apoptosis 21, 1203\u20131213 (2016).","journal-title":"Apoptosis"},{"key":"1421_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3892\/br.2015.561","volume":"4","author":"Y Tursynbay","year":"2016","unstructured":"Tursynbay, Y. et al. Pim-1 kinase as cancer drug target: an update. Biomed. Rep. 4, 140\u2013146 (2016).","journal-title":"Biomed. Rep."},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","volume":"571","author":"TL Aho","year":"2004","unstructured":"Aho, T. L. et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 571, 43\u201349 (2004).","journal-title":"FEBS Lett."},{"key":"1421_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2018.12.015","volume":"444","author":"L Cao","year":"2019","unstructured":"Cao, L. et al. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway. Cancer Lett. 444, 116\u2013126 (2019).","journal-title":"Cancer Lett."},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1038\/onc.2010.279","volume":"29","author":"V Iadevaia","year":"2010","unstructured":"Iadevaia, V. et al. PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression. Oncogene 29, 5490\u20135499 (2010).","journal-title":"Oncogene"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"7460","DOI":"10.4049\/jimmunol.1000885","volume":"185","author":"K Kim","year":"2010","unstructured":"Kim, K., Kim, J. H., Youn, B. U., Jin, H. M. & Kim, N. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-\u03baB activation and NFATc1 induction. J. Immunol. 185, 7460\u20137466 (2010).","journal-title":"J. Immunol."},{"key":"1421_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/s12276-022-00893-y","volume":"54","author":"R Ko","year":"2022","unstructured":"Ko, R., Seo, J., Park, H., Lee, N. & Lee, S. Y. Pim1 promotes IFN-beta production by interacting with IRF3. Exp. Mol. Med. 54, 2092\u20132103 (2022).","journal-title":"Exp. Mol. Med."},{"key":"1421_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.yexcr.2016.02.018","volume":"342","author":"NM Santio","year":"2016","unstructured":"Santio, N. M. et al. The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways. Exp. Cell Res. 342, 113\u2013124 (2016).","journal-title":"Exp. Cell Res."},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"20635","DOI":"10.1074\/jbc.M709479200","volume":"283","author":"M Zemskova","year":"2008","unstructured":"Zemskova, M., Sahakian, E., Bashkirova, S. & Lilly, M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283, 20635\u201320644 (2008).","journal-title":"J. Biol. Chem."},{"key":"1421_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41388-023-02914-0","volume":"43","author":"SS Chauhan","year":"2024","unstructured":"Chauhan, S. S. et al. PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer. Oncogene 43, 406\u2013419 (2024).","journal-title":"Oncogene"},{"key":"1421_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-248","volume":"10","author":"J Kim","year":"2010","unstructured":"Kim, J., Roh, M. & Abdulkadir, S. A. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 10, 248 (2010).","journal-title":"BMC Cancer"},{"key":"1421_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00618-6","volume":"18","author":"NM Santio","year":"2020","unstructured":"Santio, N. M. et al. PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins. Cell Commun. Signal. 18, 121 (2020).","journal-title":"Cell Commun. Signal."},{"key":"1421_CR34","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.cellsig.2011.05.017","volume":"23","author":"HK Choi","year":"2011","unstructured":"Choi, H. K., Kim, T. H., Jhon, G. J. & Lee, S. Y. Reactive oxygen species regulate M-CSF-induced monocyte\/macrophage proliferation through SHP1 oxidation. Cell. Signal. 23, 1633\u20131639 (2011).","journal-title":"Cell. Signal."},{"key":"1421_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7765","volume":"6","author":"R Ko","year":"2015","unstructured":"Ko, R., Park, J. H., Ha, H., Choi, Y. & Lee, S. Y. Glycogen synthase kinase 3\u03b2 ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production. Nat. Commun. 6, 6765 (2015).","journal-title":"Nat. Commun."},{"key":"1421_CR36","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon.10.106","volume":"6","author":"NS Magnuson","year":"2010","unstructured":"Magnuson, N. S., Wang, Z., Ding, G. & Reeves, R. Why target PIM1 for cancer diagnosis and treatment? Fut. Oncol. 6, 1461\u20131478 (2010).","journal-title":"Fut. Oncol."},{"key":"1421_CR37","doi-asserted-by":"crossref","unstructured":"Kim, J. M., Lin, C., Stavre, Z., Greenblatt, M. B. & Shim, J. H. Osteoblast\u2013osteoclast communication and bone homeostasis. Cells 9, 2073 (2020).","DOI":"10.3390\/cells9092073"},{"key":"1421_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo, T. R. & Chen, C. H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark. Res. 5, 18 (2017).","journal-title":"Biomark. Res."},{"key":"1421_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1084\/jem.186.4.489","volume":"186","author":"T Kameda","year":"1997","unstructured":"Kameda, T. et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186, 489\u2013495 (1997).","journal-title":"J. Exp. Med."},{"key":"1421_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1210\/me.2007-0237","volume":"22","author":"K Kim","year":"2008","unstructured":"Kim, K., Lee, S. H., Ha Kim, J., Choi, Y. & Kim, N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 22, 176\u2013185 (2008).","journal-title":"Mol. Endocrinol."},{"key":"1421_CR41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","volume":"11","author":"TJ Martin","year":"2005","unstructured":"Martin, T. J. & Sims, N. A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76\u201381 (2005).","journal-title":"Trends Mol. Med."},{"key":"1421_CR42","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1242\/jcs.109.2.301","volume":"109","author":"J Salo","year":"1996","unstructured":"Salo, J., Metsikko, K., Palokangas, H., Lehenkari, P. & Vaananen, H. K. Bone-resorbing osteoclasts reveal a dynamic division of basal plasma membrane into two different domains. J. Cell Sci. 109, 301\u2013307 (1996).","journal-title":"J. Cell Sci."},{"key":"1421_CR43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ejcb.2008.01.001","volume":"87","author":"F Saltel","year":"2008","unstructured":"Saltel, F., Chabadel, A., Bonnelye, E. & Jurdic, P. Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation. Eur. J. Cell Biol. 87, 459\u2013468 (2008).","journal-title":"Eur. J. Cell Biol."},{"key":"1421_CR44","doi-asserted-by":"crossref","unstructured":"Jensen, C. C. et al. PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion. J. Cell Biol. 222, e202203052 (2023).","DOI":"10.1083\/jcb.202208136"},{"key":"1421_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1369\/0022155411405334","volume":"59","author":"T Akisaka","year":"2011","unstructured":"Akisaka, T., Yoshida, H. & Takigawa, T. Differential distribution of posttranslationally modified microtubules in osteoclasts. J. Histochem. Cytochem. 59, 630\u2013638 (2011).","journal-title":"J. Histochem. Cytochem."},{"key":"1421_CR46","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1016\/j.clml.2013.05.019","volume":"13","author":"F Cervantes-Gomez","year":"2013","unstructured":"Cervantes-Gomez, F., Chen, L. S., Orlowski, R. Z. & Gandhi, V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 13, S317\u2013S329 (2013).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1421_CR47","first-page":"362","volume":"119","author":"XF Hu","year":"2009","unstructured":"Hu, X. F. et al. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J. Clin. Invest. 119, 362\u2013375 (2009).","journal-title":"J. Clin. Invest."},{"key":"1421_CR48","doi-asserted-by":"publisher","first-page":"23837","DOI":"10.18632\/oncotarget.8070","volume":"7","author":"V Sagar","year":"2016","unstructured":"Sagar, V. et al. PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells. Oncotarget 7, 23837\u201323849 (2016).","journal-title":"Oncotarget"},{"key":"1421_CR49","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1126\/science.1175065","volume":"325","author":"WL Yang","year":"2009","unstructured":"Yang, W. L. et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134\u20131138 (2009).","journal-title":"Science"},{"key":"1421_CR50","doi-asserted-by":"crossref","unstructured":"Busch, J. et al. TRAF6 phosphorylation prevents its autophagic degradation and re-shapes LPS-triggered signaling networks. Cancers 13, 3618 (2021).","DOI":"10.3390\/cancers13143618"},{"key":"1421_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/ni.3097","volume":"16","author":"S Jiao","year":"2015","unstructured":"Jiao, S. et al. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat. Immunol. 16, 246\u2013257 (2015).","journal-title":"Nat. Immunol."},{"key":"1421_CR52","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1038\/s41388-018-0167-6","volume":"37","author":"K Yao","year":"2018","unstructured":"Yao, K. et al. RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation. Oncogene 37, 3501\u20133513 (2018).","journal-title":"Oncogene"},{"key":"1421_CR53","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s42003-021-02723-9","volume":"4","author":"SE Ruff","year":"2021","unstructured":"Ruff, S. E., Vasilyev, N., Nudler, E., Logan, S. K. & Garabedian, M. J. PIM1 phosphorylation of the androgen receptor and 14-3-3 zeta regulates gene transcription in prostate cancer. Commun. Biol. 4, 1221 (2021).","journal-title":"Commun. Biol."},{"key":"1421_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jbior.2017.06.003","volume":"65","author":"MA Hermida","year":"2017","unstructured":"Hermida, M. A., Dinesh Kumar, J. & Leslie, N. R. GSK3 and its interactions with the PI3K\/AKT\/mTOR signalling network. Adv. Biol. Regul. 65, 5\u201315 (2017).","journal-title":"Adv. Biol. Regul."},{"key":"1421_CR55","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.2147\/OTT.S203142","volume":"12","author":"W Jiang","year":"2019","unstructured":"Jiang, W. et al. Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K\/AKT\/mTOR pathway. Onco Targets Ther. 12, 3043\u20133050 (2019).","journal-title":"Onco Targets Ther."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01421-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T08:37:25Z","timestamp":1746520645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01421-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01421-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}